Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

Our experience with the Z-Flex 690TAY toric intraocular lens

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Pseudophakic IOLs Toric

Session Date/Time: Sunday 06/09/2015 | 16:30-18:30

Paper Time: 17:22

Venue: Room 16

First Author: : P.Vámosi SWITZERLAND

Co Author(s): :                        

Abstract Details


To evaluate the mid-term clinical outcomes and rotational stability of the Z-Flex 690TAY toric intraocular lens (T-IOL) to correct pre-existing astigmatism in cataract patients.


Péterfy Sándor Hospital, Budapest, Hungary


Phacoemulsification with implantation of the hydrophilic acrylic Z-Flex 690TAY T-IOL (Medicontur) was performed by a single surgeon in cataract patients with corneal astigmatism. There was a congenital astigmatism on 113 eyes, and the astigmatism had another origin on 12 eyes. Amblyopia was revealed on 26 eyes. The prospective follow-up was up to 6 months.


This study involved 125 eyes of 89 patients with a mean age of 68.0 years ± 7.2 (SD). The mean corneal cylinder was 2.89 D±2.75 preoperatively, while the mean refractive cylinder was 0.65 D±0.56 at 6 months postoperatively. The mean uncorrected distant visual acuity was 0.56 ±0.22 at 1-day, 0.66 ±0.20 at 1-week and 0.64 ±0.25 at 1-month, and 0.62 ±0.27 at 6-month-control. Rotation of more than 5 degrees was in 3 eyes (2.4%) two of them had an axial length of more than 26.0 mm. All of them were evaluated on the 1-day-control.


The Z-Flex 690TAY T-IOL was effective in reducing pre-existing corneal astigmatism and had an overall good rotational stability. In our experience this type of T-IOL can rotate only in the very early postoperative period, and the rotation occurs mostly on highly myopic eyes.

Financial Interest:

One of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous